RET and neoplasm: Given the activation of multiple growth-factor receptor pathways in tumours with elevated epithelial cell-intrinsic TGFβ signalling, we first treated tamoxifen-induced VilCreER;Apcfl/+;KrasG12D/+;Alk5CA mice with vandetanib/ZD6474, a small-molecule tyrosine kinase inhibitor selective for VEGFR, RET, and EGFR, until clinical symptoms manifested.